Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series LLC LTD Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series LLC LTD : World’s leading Event Organizer


15th International Conference on Orthopedics, Arthroplasty and Rheumatology

Rome, Italy


Hospital Santa Creu i Sant Pau, Barcelona

Title: Ustekinumab and TNF Inhibitor Treatment in Spanish Patients with Psoriatic Arthritis: 6-month Follow-up from the Real-world Observational Study PsABio


Biography: A.Laiz


PsABio (ClinicalTrials: NCT02627768) is a prospective, observational, real-world cohort study collecting data on patients with a confirmed diagnosis of PsA starting either ustekinumab (UST) or a new TNF inhibitor (TNFi) in 8 European countries. The purpose of the study PsABio is to evaluate the efficacy, tolerability and persistence of ustekinumab and TNFis for adult patients with PsA according to CASPAR criteria commencing first-, second- or third- line bDMARDs in real-world routine clinical management.

This interim analysis presents 6-month follow-up data on joint-related outcomes in the Spanish cohort.